The Implantable Miniature Telescope Market report provides in-depth analysis of parent market trends, macro-economic indicators and governing factors along with market attractiveness as per segments. The report also maps the qualitative impact of various market factors on market segments and geographies.
New York, NY -- (SBWIRE) -- 03/09/2017 -- Implantable Miniature Telescope Market: Dynamics
Advanced age-related macular degeneration (AMD), neovascular AMD or geographic atrophy affects as many as 1.9 million people in the USA and is bilateral in at least 35% of these people. Several therapies, such as photodynamic therapy, laser photocoagulation, and intravitreal anti-vascular endothelial growth factor injections are commercially available for the treatment. An implantable miniature telescope prosthetic device is designed specifically for patients with end-stage AMD. The initial US approval limited the indication to patients older than 75 years of age because of concerns about potential safety risks in a younger cohort. Approvals by Canadian and European regulatory health authorities included younger age groups. However though the IMT can restore vision to some extent in patients with bilateral end-stage AMD, it cannot prevent the macula from further deterioration and is not considered a curative treatment.
Implantable Miniature Telescope Market: Key Players
The key player in implantable miniature telescope market is VisionCare Ophthalmic Technologies, Inc. Over 260 of the company's telescope implants have been used in clinical trials that have generated extensive long-term safety and efficacy data. The pivotal IMT002 clinical trial, conducted across 28 leading U.S. ophthalmic centers, demonstrated the majority of patients gained at least three lines of visual acuity on the study eye chart and clinically meaningful quality of life improvements on the National Eye Institute Visual Function Questionnaire. Most patients also gain improved facial recognition. Although it is not a cure for the disease, the implantable telescope has the potential to make a positive difference in the lives of people with end-stage AMD. VisionCare has initiated a patient education and support program about end-stage AMD and the implantable miniature telescope called CentraSight. Through the program, patients can see if they meet eligibility criteria and experience a simulation of what vision would be like with the implantable miniature telescope.
A Sample of this Report is Available Upon Request @ http://www.persistencemarketresearch.com/samples/14239
Implantable Miniature Telescope Market: Region-wise Outlook
Geographically, the market is segmented into North America, Europe, Asia-Pacific, Latin America and the Middle-East & Africa. North America holds the major share of the market for implantable miniature telescope market followed by Europe. The implantable telescope is the first medical device to be recommended by the panel for FDA approval for end-stage AMD in the U.S. and Australia and later in Europe.
Browse Full Report summary and to request sample report and table of content@ http://www.persistencemarketresearch.com/market-research/implantable-miniature-telescope-market.asp